Jan 06, 2022 8:00am EST Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101
Dec 15, 2021 8:16am EST Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma
Dec 09, 2021 8:00am EST Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium
Dec 06, 2021 8:00am EST Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Dec 01, 2021 4:05pm EST Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference
Nov 10, 2021 4:05pm EST Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
Oct 29, 2021 11:00am EDT Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research
Oct 12, 2021 8:00am EDT Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program
Oct 04, 2021 8:00am EDT Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021
Sep 13, 2021 4:05pm EDT Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021
